Review Article
Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease
Figure 2
Effect of the synthetic CB1/CB2 cannabinoid HU-210 on ChAT and PKC immunoreactivity. (a) ChAT immunoreactivity. ChAT immunoreactivity in control tissue ((A) ) is localized in cholinergic amacrine cell somata in the INL and GCL, as well as in their processes in the IPL. (B) Chemical ischemia mixture () caused a reduction of ChAT immunoreactivity as revealed by loss of cholinergic cell somata and less intense signal in cell processes. HU-210 afforded neuroprotection at the concentrations of 10−6 M ((C) ), 10−5 M ((D) ), and 10−4 M ((E) ). Arrows depict ChAT-immunoreactive amacrine cells. (b) PKC immunoreactivity. PKC immunoreactivity in control tissue ((A) ) is localized in rod bipolar cells in the OPL and in their axons extending toward the IPL. Reduced immunoreactivity is observed in the presence of the chemical ischemia mixture ((B) ). HU-210 afforded neuroprotection at all of concentrations used (10−6 M ((C) ), 10−5 M ((D) ), and 10−4 M ((E) )). Scale bar: 50 μm. OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer.
| (a) |
| (b) |